VIVOSIM LABS INC
VIVSNASDAQTrading Snapshot
- Day Range
- $0.22 – $0.22
- 52-Week Range
- $0.22 – $3.54
- Volume
- $3.26B
- Avg Volume
- $4.20B
- Shares Outstanding
- 2.6M
- Next Earnings
- Nov 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $131,000
- Last Q Revenue
- $18,000
- P/E Ratio
- -0.0
- P/S Ratio
- 5.1x
- EPS (TTM)
- $-2.35
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +258.0%
Why Investors Own VIVS
- ✓High-growth profile — revenue up +42.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 55% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VIVOSIM LABS INC
VIVS
StockOtter · stockotter.spaceAbout VIVOSIM LABS INC
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
VIVOSIM LABS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift VIVS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
VIVOSIM LABS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.